Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study

Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Related Keywords

Marka Socinski , ,First Line Treatment ,Mutated Advanced ,Primary Results From ,Randomized Phase ,Papillon Study ,Papillon Trial ,Advanced Non Small Cell Lung Cancer ,Advanced Nsclc ,Egfr Exon 20 Insertion Mutated Advanced Nsclc ,Egfr Exon 20 Insertion Mutations ,Chemotherapy ,Amivantamab ,Bispecific Antibody ,Safety Profile ,Amivantamab Safety Provile ,